| Followers | 71 |
| Posts | 9111 |
| Boards Moderated | 0 |
| Alias Born | 03/06/2016 |
Wednesday, June 12, 2024 7:13:11 PM
As I said, if it was that simple, Wes Christian would have to find a new line of work.
It's not simple because not every one votes. If 100% of shares voted, then it would be simple...
In fact, here is a breakdown:
Proxy voting participation historically tends to be on the lower side compared to the total number of outstanding shares.
Average Participation: It's difficult to pinpoint a single, definitive average, but studies suggest participation falls around 30-40% of outstanding shares].
Recent Trends: There have been some fluctuations. For instance, participation reached a record high of 40% in 2021 but dipped to 34% in 2022.
Retail vs. Institutional Investors: Generally, institutional investors (like mutual funds) have a higher voting participation rate compared to retail investors (individual shareholders.
...
I'm hoping (due to the emotional sensitively of this proxy) we will see a huge voter participation...at least 60%.
So, if 1B naked shorts do exists, and around 60% of shareholders vote...Then 60% of 2.2B (1.2B Outstanding shares + 1B naked shorts shares) would indicate at least 100M naked shorts...(2.2B x 60% = 1.3B less 1.2B outstanding = 100M naked....
If we get 80% voter participation then that would indicate 500M naked shorts. (if 1B naked shorts are true)...
In any event, If the total tally on any individual item exceeds 1.2B then that would indicate a naked short position does exit...
Let's hope the compensation items on the proxy brings forth a higher than normal voting. If it does, then hopefully we will see if a sizable naked short position exits...
Just VOTE!!!
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
